Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
Teijin said on May 11 that it will seek a new owner for its legacy pharmaceutical portfolio, including diabetes, osteoporosis, and gout drugs, as the company sharpens its focus on rare and intractable diseases under a new three-year business plan…
To read the full story
Related Article
- Teijin Slashes FY2025 Forecast on Pharma Impairment
April 2, 2026
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
- Teijin Earns Japan Rights to 3 Hormone Therapies from Denmark’s Ascendis
November 30, 2023
- Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
BUSINESS
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
- Meiji Backs US Fund Supporting Pandemic Preparedness
June 1, 2026
- Kaken, Gilead Ink Japan Sales Partnership for Seladelpar
June 1, 2026
- Shionogi’s OIC Drug Naldemedine Bags Approval in China
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…